Halozyme Therapeutics
As of the edition of 20 October 2026, Halozyme Therapeutics runs 8 drugs, 6 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Antares Pharma Inc.: acquired in 2022; successor Halozyme Therapeutics
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Stopped | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Testosterone | none listed | 4 |
| Hyaluronidase (human recombinant) | Ended 2017 (computed from the first US licence) | 0 |
| Oxybutynin | none listed | 3 |
| Testosterone undecanoate | none listed | 2 |
| Testosterone enanthate | none listed | 1 |
A route B row is one company at one target.
Where its trials are
- Cancer: 9 trials led
- Digestive system: 4 trials led
- Hormones: 3 trials led